Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Recent & Breaking News (NYSEAM:TOVX)

Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire February 16, 2023

Theriva Biologics to Participate in the B. Riley Securities 3rd Annual Oncology Conference

GlobeNewswire January 17, 2023

Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

GlobeNewswire January 17, 2023

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

GlobeNewswire January 9, 2023

Theriva Biologics to Participate in Upcoming Investor Conferences

GlobeNewswire December 1, 2022

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire November 10, 2022

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire November 10, 2022

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire November 3, 2022

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire November 3, 2022

Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics

GlobeNewswire October 31, 2022

Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

GlobeNewswire October 24, 2022

Synthetic Biologics Rebrands as Theriva Biologics

GlobeNewswire October 12, 2022

Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

GlobeNewswire September 30, 2022

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

GlobeNewswire September 27, 2022

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

GlobeNewswire September 5, 2022

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire August 11, 2022

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

GlobeNewswire August 4, 2022

Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

GlobeNewswire August 4, 2022

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

GlobeNewswire July 29, 2022

Synthetic Biologics Announces Reverse Stock Split

GlobeNewswire July 15, 2022